Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.
Company profile
Ticker
XAIR
Exchange
Website
CEO
Steven Lisi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AIT Therapeutics, Inc., KokiCare, Inc.
SEC CIK
Corporate docs
Subsidiaries
Beyond Air Ltd. • Beyond Air Ireland Limited • Beyond Air Australia • Beyond Cancer Bermuda Limited • Beyond Cancer U.S., Inc. • XAIR Israel Ltd • Beyond Cancer Cyprus Limited ...
XAIR stock data
Latest filings (excl ownership)
8-K
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
22 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Beyond Air® Reports Financial Results
16 Feb 24
10-Q
2024 Q3
Quarterly report
12 Feb 24
DEFA14A
Additional proxy soliciting materials
8 Feb 24
DEF 14A
Definitive proxy
26 Jan 24
S-8
Registration of securities for employees
20 Dec 23
8-K
Beyond Air® Reports Financial Results
17 Nov 23
Transcripts
XAIR
Earnings call transcript
2024 Q3
12 Feb 24
XAIR
Earnings call transcript
2024 Q2
13 Nov 23
XAIR
Earnings call transcript
2024 Q1
10 Aug 23
XAIR
Earnings call transcript
2023 Q4
22 Jun 23
XAIR
Earnings call transcript
2023 Q3
9 Feb 23
XAIR
Earnings call transcript
2023 Q2
8 Nov 22
XAIR
Earnings call transcript
2023 Q1
12 Aug 22
XAIR
Earnings call transcript
2022 Q4
29 Jun 22
XAIR
Earnings call transcript
2022 Q3
11 Feb 22
XAIR
Earnings call transcript
2022 Q2
12 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.59 mm | 31.59 mm | 31.59 mm | 31.59 mm | 31.59 mm | 31.59 mm |
Cash burn (monthly) | 11.28 mm | 1.54 mm | 5.85 mm | 5.12 mm | 4.77 mm | 4.04 mm |
Cash used (since last report) | 77.29 mm | 10.53 mm | 40.04 mm | 35.06 mm | 32.70 mm | 27.64 mm |
Cash remaining | -45.70 mm | 21.06 mm | -8.45 mm | -3.47 mm | -1.11 mm | 3.95 mm |
Runway (months of cash) | -4.1 | 13.7 | -1.4 | -0.7 | -0.2 | 1.0 |
Institutional ownership, Q2 2023
29.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 64 |
Opened positions | 22 |
Closed positions | 12 |
Increased positions | 18 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 40.68 bn |
Total shares | 10.50 mm |
Total puts | 87.00 k |
Total calls | 62.80 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 1.73 mm | $7.36 bn |
Kingdon Capital Management, L.L.C. | 1.36 mm | $5.81 bn |
Vanguard | 1.31 mm | $5.57 bn |
Gendell Jeffrey L | 863.34 k | $3.68 bn |
Millennium Management | 844.65 k | $3.60 bn |
Flynn James E | 833.33 k | $7.87 mm |
Geode Capital Management | 501.41 k | $2.14 bn |
DB Deutsche Bank AG - Registered Shares | 400.00 k | $1.70 bn |
STT State Street | 368.15 k | $1.57 bn |
Wealth Effects | 323.05 k | $1.38 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Lisi Steven A. | Common Stock | Grant | Acquire A | No | No | 1.66 | 78,314 | 130.00 k | 1,614,785 |
20 Mar 24 | Lisi Steven A. | Warrants Common Stock | Grant | Acquire A | No | No | 2.25 | 78,314 | 176.21 k | 78,314 |
20 Mar 24 | Carey Robert | Common Stock | Grant | Acquire A | No | No | 1.66 | 602,410 | 1.00 mm | 2,976,864 |
20 Mar 24 | Carey Robert | Warrants Common Stock | Grant | Acquire A | No | No | 2.25 | 602,410 | 1.36 mm | 602,410 |
20 Mar 24 | Douglas Quinton Larson | Common Stock | Grant | Acquire A | No | No | 1.66 | 12,048 | 20.00 k | 27,548 |
20 Mar 24 | Douglas Quinton Larson | Warrants Common Stock | Grant | Acquire A | No | No | 2.25 | 12,048 | 27.11 k | 12,048 |
20 Mar 24 | Lisi Steven A. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.53 | 950,000 | 1.45 mm | 950,000 |
20 Mar 24 | Michael A. Gaul | Stock Option Common Stock | Grant | Acquire A | No | No | 1.53 | 350,000 | 535.50 k | 350,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
14 Feb 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
13 Feb 24
Beyond Air Reiterates FY25 Revenue Guidance Of $12M-$16M Vs $13.82M Est.
12 Feb 24
Beyond Air Q3 EPS $(0.50) Beats $(0.53) Estimate, Sales $391.00K Miss $450.00K Estimate
12 Feb 24
12 Health Care Stocks Moving In Monday's After-Market Session
12 Feb 24